OVA-LEAK: Prognostic score for colo-rectal anastomotic leakage in patients undergoing ovarian cancer surgery.


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
10 2022
Historique:
received: 07 06 2022
revised: 31 07 2022
accepted: 07 08 2022
pubmed: 5 9 2022
medline: 5 10 2022
entrez: 4 9 2022
Statut: ppublish

Résumé

The objective of the present study was to define and validate an anastomotic leak prognostic score based on previously described and reported anastomotic leak risk factors (OVA-LEAK: https://n9.cl/ova-leakscore) and to establish if the use of OVA-LEAK score is better than clinical criteria (surgeon's choice) selecting anastomosis to be protected with a diverting ileostomy. This is a retrospective, multicentre cohort study that included patients who underwent cytoreductive surgery for primary advanced or relapsed ovarian cancer with colorectal resection and anastomosis between January 2011 and June 2021. Data from patients already included in the previous predictive model were not considered in the present analysis. To validate the performance of our logistic regression model, we used the OVA-LEAK formula (Annex I: https://n9.cl/ova-leakscore) for estimating leakage probabilities in a new independent cohort. Then, receiver operating characteristic (ROC) analysis was performed and area under the curve (AUC) was used to measure the performance of the model. Additionally, the Brier score was also estimated. 95% confidence intervals (CI) for each of the estimated performance measures were also calculated. 848 out of 1159 recruited patients were finally included in the multivariable logistic regression model validation. The AUC of the new cohort was 0.63 for predicting anastomotic leak. Considering a cut-off point of 22.1% to be 'positive' (to get a leak) this would provide a sensitivity of 0.45, specificity of 0.80, positive predictive value of 0.09 and negative predictive value of 0.97 for anastomotic leak. If we consider this cut-off point to select patients at risk of leak for bowel diversion, up to 22.5% of the sampled patients would undergo a diverting ileostomy and 47% (18/40) of the anastomotic leaks would be 'protected' with the stoma. Nevertheless, if we consider only the 'clinical criteria' for performing or not a diverting ileostomy, only 12.5% (5/40) of the leaks would be 'protected' with a stoma, with a rate of diverting ileostomy of up to 24.3%. Compared with subjective clinical criteria, the use of a predictive model for anastomotic leak improves the selection of patients who would benefit from a diverting ileostomy without increasing the rate of stoma use.

Identifiants

pubmed: 36058743
pii: S0090-8258(22)00542-X
doi: 10.1016/j.ygyno.2022.08.004
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

22-27

Investigateurs

Antonio Gil-Moreno (A)
Luis Chiva (L)
Natasha Rinne (N)
Alejandra Martinez (A)
Luis Matute (L)
Marta Gurrea (M)
L Sala Climent (L)
Manel Montesinos (M)

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Víctor Lago (V)

Department of Gynecologic Oncology Department, University Hospital La Fe, Valencia, Spain; CEU Cardenal Herrera, Spain. Electronic address: victor.lago.leal@hotmail.com.

Blanca Segarra-Vidal (B)

Department of Gynecologic Oncology Department, University Hospital La Fe, Valencia, Spain.

Serena Cappucio (S)

Fondazione Policlinico Universitario A. Gemelli, IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy.

Martina Aida Angeles (MA)

Department of Surgical Oncology, Institut Claudius Regaud - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France.

Christina Fotopoulou (C)

Department of Gynecologic Oncology, Imperial College London, London, United Kingdom.

Mustafa Zelal Muallem (MZ)

Department of Gynecology with Centre for Oncological Surgery, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Virchow Campus Clinic, Charité Medical University, Berlin, Germany.

Israel Manzanedo (I)

Department of General and Digestive Surgery, Peritoneal Carcinomatosis Unit, Hospital Universitario de Fuenlabrada, Madrid, Spain.

Jose Luis Sanchez Iglesias (JLS)

Department of Obstetrics and Gynecology, Vall d'Hebron, Barcelona, Spain.

Enrique Chacón (E)

Department of Obstetrics and Gynecology, University Clinic of Navarra, Madrid, Navarre, Spain.

Pablo Padilla-Iserte (P)

Department of Gynecologic Oncology Department, University Hospital La Fe, Valencia, Spain.

Anna Fagotti (A)

Fondazione Policlinico Universitario A. Gemelli, IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy.

Gwenael Ferron (G)

Department of Surgical Oncology, Institut Claudius Regaud - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France.

Luisa Kluge (L)

Department of Gynecology with Centre for Oncological Surgery, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Virchow Campus Clinic, Charité Medical University, Berlin, Germany.

Virginia Vargiu (V)

Fondazione Policlinico Universitario A. Gemelli, IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy.

Mathilde Del (M)

Department of Surgical Oncology, Institut Claudius Regaud - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France.

Giovanni Scambia (G)

Fondazione Policlinico Universitario A. Gemelli, IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy.

Lucas Minig (L)

Department of Gynecology, IMED Hospitales, Valencia, Spain.

Álvaro Tejerizo (Á)

Department of Obstetrics and Gynecology, Hospital 12 de Octubre, Madrid, Spain.

Myriam García Segovia (MG)

Gynaecologic Oncology Unit, La Paz University Hospital - IdiPAZ, Madrid, Spain.

Pedro Antonio Cascales-Campos (PA)

Department of General Surgery, Virgen de la Arrixaca Clinic and University Hospital, Murcia, Spain.

David Hervás (D)

Department of Applied Statistics and Operational Research and Quality, Universitat Politècnica de València, Valencia, Spain.

Santiago Domingo (S)

Department of Gynecologic Oncology Department, University Hospital La Fe, Valencia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH